Raising awareness about pancreatic cancer and the urgent need for earlier detection continues to be a critical part of PRECEDE’s mission. Recently, PRECEDE Founder and Chief Scientific Advisor Dr. Diane Simeone was featured in HealthyWomen, where she shares key insights on what people need to know about this complex disease.
In the article, “Clinically Speaking: Questions and Answers About Pancreatic Cancer”, Dr. Simeone discusses why pancreatic cancer is so often detected at a late stage and why that must change. While the disease is currently the third deadliest cancer in the United States, outcomes improve significantly when it is identified early.
Why Early Detection Matters
One of the key takeaways from the feature is the critical role of early detection. Symptoms of pancreatic cancer are often vague—such as abdominal discomfort or bloating—and typically don’t appear until the disease has progressed.
Dr. Simeone highlights several important warning signs to watch for, including:
- New-onset diabetes accompanied by unexplained weight loss
- Jaundice (yellowing of the skin or eyes)
- Subtle digestive symptoms that persist over time
These insights reinforce a central challenge: pancreatic cancer is frequently diagnosed too late, limiting treatment options and survival rates.
Understanding Risk Factors
The article also emphasizes the importance of identifying individuals at higher risk. According to Dr. Simeone, genetics and family history play a meaningful role, with inherited factors contributing to a notable percentage of cases.
Conditions like Type 2 diabetes and chronic pancreatitis can also increase risk, underscoring the need for more personalized screening approaches and better risk stratification.
The Role of Research and Collaboration
Dr. Simeone points to ongoing research and clinical trials as essential to improving outcomes. Efforts like the PRECEDE Consortium are focused on advancing early detection through collaboration, data sharing, and innovative screening strategies.
PRECEDE’s global model brings together leading institutions to better identify high-risk individuals and develop tools that can detect pancreatic cancer earlier—when it is most treatable. This includes research into biomarkers, imaging, and genetic risk assessment, all aimed at shifting diagnosis to earlier stages of the disease.
Empowering Patients Through Awareness
A powerful message from the HealthyWomen feature is the importance of patient advocacy. Dr. Simeone encourages individuals to listen to their bodies, seek second opinions when necessary, and ask about screening options—especially if they have known risk factors.
Improving outcomes in pancreatic cancer will require not only scientific advancement, but also greater awareness and education. By sharing expert insights through platforms like HealthyWomen, we can help more people recognize potential warning signs and understand their risk.
Read the full interview on HealthyWomen
